Pilot Study of Comprehensive Geriatric Assessment (CGA) in Allogeneic Transplant: CGA Captures a High Prevalence of Vulnerabilities in Older Transplant Recipients
Muffly, L. S., Boulukos, M., Swanson, K., Kocherginsky, M., del Cerro, P., Schroeder, L., … Artz, A. S. (2013). Pilot Study of Comprehensive Geriatric Assessment (CGA) in Allogeneic Transplant: CGA Captures a High Prevalence of Vulnerabilities in Older Transplant Recipients. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19(3), 429–434.

Patient Selection for Allogeneic Hematopoietic Cell Transplantation (HCT): the Evolution of HCT Risk Assessment.
Muffly, L. (2015). Patient Selection for Allogeneic Hematopoietic Cell Transplantation (HCT): the Evolution of HCT Risk Assessment. Current Hematologic Malignancy Reports, 10(1), 28–34.

Secondary solid cancer screening following hematopoietic cell transplantation.
INAMOTO, Y., Shah, N. N., Savani, B. N., Shaw, B. E., Abraham, A. A., Ahmed, I. A., … Majhail, N. S. (2015). Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplantation, 50(8), 1013–23.

Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients
Muffly, L. S., Kocherginsky, M., Stock, W., Chu, Q., Bishop, M. R., Godley, L. A., … Artz, A. S. (2014). Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. HAEMATOLOGICA, 99(8), 1373–1379.

Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship.
Muffly, L. S., Hlubocky, F. J., Khan, N., Wroblewski, K., Breitenbach, K., Gomez, J., … Daugherty, C. K. (2016). Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship. Cancer, 122(6), 954–61.

The overlooked COST of multiple myeloma.
de Souza, J. A., & Muffly, L. (2015). The overlooked COST of multiple myeloma. The Lancet. Haematology, 2(10), e394–5.

Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study.
Muffly, L., Lichtensztajn, D., Shiraz, P., Abrahão, R., McNeer, J., Stock, W., … Gomez, S. L. (2016). Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study. Cancer.

Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
CJ, L., P, S., & L, M. (2017). Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leuk Lymphoma, 58(3).

My Patient, the Superhero.
Muffly, L. (2017). My Patient, the Superhero. Journal of Clinical Oncology , JCO2016696005-?

Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.
Lee, C. J., Shiraz, P., & Muffly, L. (2017). Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leukemia & Lymphoma, 58(3), 516–27.

Adoption of Pediatric-Inspired Acute Lymphoblastic Leukemia Regimens by Adult Oncologists Treating Adolescents and Young Adults: A Population-Based Study
Muffly, L., Lichtensztajn, D., Shiraz, P., Abrahao, R., McNeer, J., Stock, W., … Gomez, S. L. (2017). Adoption of Pediatric-Inspired Acute Lymphoblastic Leukemia Regimens by Adult Oncologists Treating Adolescents and Young Adults: A Population-Based Study. CANCER, 123(1), 122–30.

Coordination of Care in Survivorship After Treatment of Hematological Malignancies-The Journey is Not Over Yet.
Lee, C. J., & Muffly, L. S. (2017). Coordination of Care in Survivorship After Treatment of Hematological Malignancies-The Journey is Not Over Yet. Current Hematologic Malignancy Reports.

HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.
Spinner, M. A., Fernández-Viña, M., Creary, L. E., Quinn, O., Elder, L., Arai, S., … Rezvani, A. R. (2017). HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Advances, 1(17), 1347–57.

Advance Directive Utilization is Associated with Less Aggressive End-of-Life Care in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation.
Cappell, K., Sundaram, V., Park, A., Shiraz, P., Gupta, R., Jenkins, P., … Muffly, L. (2018). Advance Directive Utilization is Associated with Less Aggressive End-of-Life Care in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.

Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin
Nakasone, H., Miklos, D. B., Meyer, E., Rezvani, A., Muffly, L., Weng, W.-K., … Lowsky, R. (2016). Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms
Narayan, R., Benjamin, J., Laport, G., Tian, L., Tate, K., Elder, L., … Meyer, E. (2015). Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms. BLOOD. AMER SOC HEMATOLOGY.

Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation
Muffly, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., … Lowsky, R. (2018). Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation. BLOOD ADVANCES, 2(6), 681–90.

Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells
Meyer, E., Laport, G. G., Tantsura, I., Tang, S. W., Sahaf, B., Rangarajan, K., … Negrin, R. S. (2018). Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Review
Siegel, S. E., Stock, W., Johnson, R. H., Advani, A., Muffly, L., Douer, D., … Bleyer, A. (2018). Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia A Review. JAMA ONCOLOGY, 4(5), 725–34.

Decreased Early Mortality Associated With the Treatment of Acute Myeloid Leukemia at National Cancer Institute-Designated Cancer Centers in California
Ho, G., Wun, T., Muffly, L., Li, Q., Brunson, A., Rosenberg, A. S., … Keegan, T. H. M. (2018). Decreased Early Mortality Associated With the Treatment of Acute Myeloid Leukemia at National Cancer Institute-Designated Cancer Centers in California. CANCER, 124(9), 1938–45.

Another reason to encourage psychosocial risk assessment in hematopoietic cell transplantation.
Muffly, L., & Artz, A. (2018). Another reason to encourage psychosocial risk assessment in hematopoietic cell transplantation. Bone Marrow Transplantation.

Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study
Muffly, L., Alvarez, E., Lichtensztajn, D., Abrahao, R., Gomez, S. L., & Keegan, T. (2018). Patterns of care and outcomes in adolescent and young adult acute lymphoblastic leukemia: a population-based study. BLOOD ADVANCES, 2(8), 895–903.

Management of Acute Lymphoblastic Leukemia in Young Adults
Muffly, L., Reizine, N., & Stock, W. (2018). Management of Acute Lymphoblastic Leukemia in Young Adults. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 16(2), 138–46.

Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation
Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., … Johnston, L. (2017). Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23(10), 1744–48.

Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy.
Hossain, N. M., Dahiya, S., Le, R., Abramian, A. M., Kong, K. A., Muffly, L. S., & Miklos, D. B. (2018). Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy. Leukemia & Lymphoma, 1–4.

Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.
Spinner, M. A., Advani, R. H., Hoppe, R. T., Lowsky, R., & Muffly, L. S. (2018). Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation. Blood Advances, 2(13), 1547–50.

Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Yurkiewicz, I. R., Muffly, L., & Liedtke, M. (2018). Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia. DRUG DESIGN DEVELOPMENT AND THERAPY, 12, 2293–2300.

Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors
Spinner, M. A., Vina, M. F., Elder, L., Arai, S., Johnston, L., Meyer, E., … Rezvani, A. R. (2016). Allogeneic Transplants from HLA-Mismatched Unrelated Donors Using Total Lymphoid Irradiation and Antithymocyte Globulin Conditioning Retain a Low Risk of Graft-Versus-Host Disease and Non-Relapse Mortality with at Least As Potent Anti-Tumor Activity As with Matched Unrelated Donors. BLOOD. AMER SOC HEMATOLOGY.

Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation
Muffly, L. S., Sheehan, K., Armstrong, R., Tate, K., Tudisco, C., Rezvani, A. R., … Lowsky, R. (2016). Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation. BLOOD. AMER SOC HEMATOLOGY.

End-of-Life Care Intensity in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Population-Level Analysis.
Johnston, E. E., Muffly, L., Alvarez, E., Saynina, O., Sanders, L. M., Bhatia, S., & Chamberlain, L. J. (2018). End-of-Life Care Intensity in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Population-Level Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018780957.

Detection of Measurable Residual Disease by Next-Generation Sequencing in Paired Blood and Bone Marrow Samples from Patients with Lymphoid Malignancies
Miklos, D., Muffly, L., Lee, L. W., & Crossley, B. (2018). Detection of Measurable Residual Disease by Next-Generation Sequencing in Paired Blood and Bone Marrow Samples from Patients with Lymphoid Malignancies. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 18, S295–S296.

Minimal Residual Disease Monitoring of Acute Lymphoblastic Leukemia by High-Throughput Sequencing of the Peripheral Blood: Case Examples and Literature Review
Muffly, L. (2018). Minimal Residual Disease Monitoring of Acute Lymphoblastic Leukemia by High-Throughput Sequencing of the Peripheral Blood: Case Examples and Literature Review. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 18, S53–S55.

Adolescent and Young Adult Oncology Patients with Acute Lymphoblastic Leukemia: Shifting Location of Care over Time
Alvarez, E., Muffly, L. S., Li, Q., Brunson, A. M., Wun, T., Chamberlain, L., & Keegan, T. (2016). Adolescent and Young Adult Oncology Patients with Acute Lymphoblastic Leukemia: Shifting Location of Care over Time. BLOOD. AMER SOC HEMATOLOGY.

A Three-Step Letter Advance Directive Procedure to Facilitate Patient-Proxy Alignment in Advance Care Planning
Alagappan, M., Richardson, M. T., Schoen, M. K., Muffly, L., Tierney, K., Jenkins, P., … Periyakoil, V. S. (2018). A Three-Step Letter Advance Directive Procedure to Facilitate Patient-Proxy Alignment in Advance Care Planning. JOURNAL OF PALLIATIVE MEDICINE.

Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens
Siegel, S. E., Advani, A., Seibel, N., Muffly, L., Stock, W., Luger, S., … Bleyer, A. (2018). Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens. AMERICAN JOURNAL OF HEMATOLOGY, 93(10), 1254–66.

Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California.
Alvarez, E., Muffly, L., Li, Q., Brunson, A., Wun, T., Chamberlain, L., & Keegan, T. (2018). Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California. Leukemia & Lymphoma, 59(10), 2482–84.

Assessment of Older Adult Candidates for Allogeneic Hematopoietic Cell Transplantation: Updates and Remaining Questions.
Kennedy, V. E., & Muffly, L. S. (2019). Assessment of Older Adult Candidates for Allogeneic Hematopoietic Cell Transplantation: Updates and Remaining Questions. Expert Review of Hematology.

Hematopoietic Cell Transplantation in Young Adult Acute Lymphoblastic Leukemia: A United States Population-Level Analysis.
Muffly, L., Li, Q., Alvarez, E., Kahn, J., Winestone, L., Cress, R., … Keegan, T. H. (2019). Hematopoietic Cell Transplantation in Young Adult Acute Lymphoblastic Leukemia: A United States Population-Level Analysis. Journal of Adolescent and Young Adult Oncology.

Rate of Rise of EBV Viral Load By Quantitative PCR after Allogeneic Transplantation Correlates with PTLD Facilitates Timely Institution of Rituximab
Muffly, L. S., Shiraz, P., Nguyen, I. T., & Brown, J. (W. M. (2016). Rate of Rise of EBV Viral Load By Quantitative PCR after Allogeneic Transplantation Correlates with PTLD Facilitates Timely Institution of Rituximab. BLOOD. AMER SOC HEMATOLOGY.

Health Care Utilization and Intensity at End of Life is High Amongst Adults Who Relapse Following Allogeneic Hematopoietic Cell Transplantation
Langston, J., Sundaram, V., Periyakoil, V., & Muffly, L. (2019). Health Care Utilization and Intensity at End of Life is High Amongst Adults Who Relapse Following Allogeneic Hematopoietic Cell Transplantation. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 57(2), 506.

Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., … Lowsky, R. (2018). Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort. BLOOD. AMER SOC HEMATOLOGY.

Hematopoietic Cell Transplantation in First Remission Amongst Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Level Analysis across the United States
Muffly, L. S., Li, Q., Alvarez, E., Kahn, J. M., Winestone, L. E., Cress, R., … Keegan, T. H. M. (2018). Hematopoietic Cell Transplantation in First Remission Amongst Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Level Analysis across the United States. BLOOD, 132.

Disparities in Cancer-Related Mortality and Long-Term Survival in Adolescent and Young Adults with Hodgkin Lymphoma: A Population-Level Analysis across the United States
Kahn, J. M., Keegan, T. H. M., Alvarez, E., Muffly, L. S., Parsons, H., Winestone, L. E., & Bleyer, A. (2018). Disparities in Cancer-Related Mortality and Long-Term Survival in Adolescent and Young Adults with Hodgkin Lymphoma: A Population-Level Analysis across the United States. BLOOD, 132.

Health Care Utilization Is High Amongst Adults Who Relapse Following Allogeneic Hematopoietic Cell Transplantation
Langston, J., Sundaram, V., Periyakoil, V., & Muffly, L. S. (2018). Health Care Utilization Is High Amongst Adults Who Relapse Following Allogeneic Hematopoietic Cell Transplantation. BLOOD, 132.

Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma
Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., … Miklos, D. B. (2018). Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma. BLOOD. AMER SOC HEMATOLOGY.

Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies
Hossain, N., Sahaf, B., Abramian, M., Spiegel, J. Y., Kong, K., Kim, S., … Miklos, D. B. (2018). Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies. BLOOD. AMER SOC HEMATOLOGY.

1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL)
Schultz, L. M., Davis, K. L., Baggott, C., Chaudry, C., Marcy, A. C., Mavroukakis, S., … Mackall, C. L. (2018). 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL). BLOOD. AMER SOC HEMATOLOGY.

Medical Conditions Among Survivors of Adolescent and Young Adult Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
Keegan, T. H. M., Muffly, L. S., Li, Q., Alvarez, E., Brunson, A. M., Malogolowkin, M., & Wun, T. (2018). Medical Conditions Among Survivors of Adolescent and Young Adult Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML). BLOOD, 132.

Impact of Myeloablative Total Body Irradiation Versus Chemotherapy on Late Effects and Survival Among Adolescent and Young Adult Survivors of Hematopoietic Cell Transplantation for Acute Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis
Lee, C. J., Kim, S., Tecca, H. R., Brazauskas, R., Battiwalla, M., Buchbinder, D. K., … Muffly, L. S. (2018). Impact of Myeloablative Total Body Irradiation Versus Chemotherapy on Late Effects and Survival Among Adolescent and Young Adult Survivors of Hematopoietic Cell Transplantation for Acute Leukemia: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. BLOOD, 132.

Decreased Early Mortality in Young Adult Patients With Acute Lymphoblastic Leukemia Treated at Specialized Cancer Centers in California.
Alvarez, E. M., Malogolowkin, M., Li, Q., Brunson, A., Pollock, B. H., Muffly, L., … Keegan, T. H. (2019). Decreased Early Mortality in Young Adult Patients With Acute Lymphoblastic Leukemia Treated at Specialized Cancer Centers in California. Journal of Oncology Practice, JOP1800264.

Does Treatment Setting Matter? Evaluating Resource Utilization for Adolescents Treated in Pediatric vs Adult Cancer Institutions.
Parsons, H. M., Muffly, L., Alvarez, E. M., & Keegan, T. H. (2019). Does Treatment Setting Matter? Evaluating Resource Utilization for Adolescents Treated in Pediatric vs Adult Cancer Institutions. Journal of the National Cancer Institute, 111(3), 224–25.

Acute leukemia in a patient with 15q overgrowth syndrome.
Bodle, E. E., Gupta, R., Cherry, A. M., Muffly, L., & Manning, M. A. (2019). Acute leukemia in a patient with 15q overgrowth syndrome. American Journal of Medical Genetics. Part A.

Integrating cancer survivorship care into allogeneic BMT recovery.
Bugos, K., Stenger, S., Smith, A. S., Johnston, L., Gross, M., Knight, G., … Muffly, L. S. (2017). Integrating cancer survivorship care into allogeneic BMT recovery. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR-T therapy.
Dahiya, S., Le, R., Hossain, N. M., Abramian, M., Muffly, L. S., & Miklos, D. B. (2017). Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR-T therapy. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Muffly, L., Pasquini, M. C., Martens, M., Brazauskas, R., Zhu, X., Adekola, K., … Artz, A. (2017). Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. BLOOD, 130(9), 1156–64.

Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes
Muffly, L., Pasquini, M. C., Martens, M., Brazauskas, R., Zhu, X., Adekola, K., … Wood, W. A. (2016). Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

Health Care Utilization is High in Adult Patients Relapsing After Allogeneic Hematopoietic Cell Transplantation.
Langston, J. A., Sundaram, V., Periyakoil, V. S., & Muffly, L. (2019). Health Care Utilization is High in Adult Patients Relapsing After Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.

Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., … Negrin, R. S. (2019). Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight, 4(10).

Decreased Early Mortality in Young Adult Patients With Acute Lymphoblastic Leukemia Treated at Specialized Cancer Centers in California
Alvarez, E. M., Malogolowkin, M., Li, Q., Brunson, A., Pollock, B. H., Muffly, L., … Keegan, T. H. M. (2019). Decreased Early Mortality in Young Adult Patients With Acute Lymphoblastic Leukemia Treated at Specialized Cancer Centers in California. JOURNAL OF ONCOLOGY PRACTICE, 15(4), 200-+.

Does Treatment Setting Matter? Evaluating Resource Utilization for Adolescents Treated in Pediatric vs Adult Cancer Institutions
Parsons, H. M., Muffly, L., Alvarez, E. M., & Keegan, T. H. M. (2019). Does Treatment Setting Matter? Evaluating Resource Utilization for Adolescents Treated in Pediatric vs Adult Cancer Institutions. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 111(3), 224–25.

Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., … Negrin, R. S. (2019). Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI INSIGHT, 4(10).

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma
Lin, J. K., Muffly, L. S., Spinner, M. A., Barnes, J. I., Owens, D. K., & Goldhaber-Fiebert, J. D. (2019). Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. Journal of Clinical Oncology.

Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
Lin, J. K., Muffly, L. S., Spinner, M. A., Barnes, J. I., Owens, D. K., & Goldhaber-Fiebert, J. D. (2019). Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1802079.

Acute leukemia in a patient with 15q overgrowth syndrome
Bodle, E. E., Gupta, R., Cherry, A. M., Muffly, L., & Manning, M. A. (2019). Acute leukemia in a patient with 15q overgrowth syndrome. AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 179(6), 1025–29.

Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation.
Veeraputhiran, M., Arai, S., Lowsky, R., Miklos, D. B., Meyer, E., Muffly, L. S., … Johnston, L. J. (2016). Validation of the hematopoietic cell transplantation-specific comorbidity index in non-myeloablative allogeneic stem cell transplantation. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma.
Neppalli, A. K., Shizuru, J., Johnston, L. J., Muffly, L. S., Weng, W.-K., Negrin, R., … Rezvani, A. R. (2016). Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Hematopoietic Cell Transplantation in Young Adult Acute Lymphoblastic Leukemia: A United States Population-Level Analysis
Muffly, L., Li, Q., Alvarez, E., Kahn, J., Winestone, L., Cress, R., … Keegan, T. H. M. (2019). Hematopoietic Cell Transplantation in Young Adult Acute Lymphoblastic Leukemia: A United States Population-Level Analysis. JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY, 8(3), 254–61.

Transplant for Acute Myeloid Leukemia in Patients Seventy Years and Older: Optimism and Opportunity.
Muffly, L. (2019). Transplant for Acute Myeloid Leukemia in Patients Seventy Years and Older: Optimism and Opportunity. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.

EEG Findings in Chimeric Antigen Receptor T-Cell (CAR-T) Related Encephalopathy Syndrome
Satyanarayan, S., Markert, M., Hovsepian, D., Post, D., Muffly, L., Miklos, D., … Scott, B. (2019). EEG Findings in Chimeric Antigen Receptor T-Cell (CAR-T) Related Encephalopathy Syndrome. NEUROLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S., Johnston, L. J., … Lowsky, R. (2019). Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort. Blood Advances, 3(16), 2454–64.

Comparison of high doses of total body irradiation in myeloablative conditioning prior to hematopoietic cell transplantation.
Sabloff, M., Chhabra, S., Wang, T., Fretham, C., Kekre, N., Abraham, A., … Loren, A. W. (2019). Comparison of high doses of total body irradiation in myeloablative conditioning prior to hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.

Healthcare Utilization is High in Adult Patients Relapsing after Allogeneic Hematopoietic Cell Transplantation
Langston, J. A., Sundaram, V., Periyakoil, V. S., & Muffly, L. (2019). Healthcare Utilization is High in Adult Patients Relapsing after Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 25(8), 1659–65.

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.
Lazaryan, A., Dolan, M., Zhang, M.-J. J., Wang, H.-L. L., Kharfan-Dabaja, M. A., Marks, D. I., … Weisdorf, D. (2019). Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica.

Central Nervous System Relapse in Adolescents and Young Adults with Acute Lymphoblastic Lymphoma Treated with Total Body Irradiation and Hematopoietic Stem Cell Transplantation
Kozak, M., Yoo, C., Muffly, L., & Hiniker, S. M. (2019). Central Nervous System Relapse in Adolescents and Young Adults with Acute Lymphoblastic Lymphoma Treated with Total Body Irradiation and Hematopoietic Stem Cell Transplantation. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 105(1), E472.

Cost-effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma.
Lin, J., Muffly, L. S., Spinner, M. A., Barnes, J. I., Owens, D. K., & Goldhaber-Fiebert, J. D. (2019). Cost-effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 37(15).

Delays in diagnosis in young patients with leukemia and lymphoma.
Winestone, L., McPheeters, J., Puccetti, D., Wilkes, J. J., Muffly, L. S., Kahn, J., … Alvarez, E. M. (2019). Delays in diagnosis in young patients with leukemia and lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 37(15).

Central Nervous System Relapse After Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: A Single-Institution Experience.
Kozak, M. M., Yoo, C. H., Gutkin, P. M., von Eyben, R., Agarwal, R., Donaldson, S. S., … Hiniker, S. M. (2019). Central Nervous System Relapse After Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: A Single-Institution Experience. Journal of Adolescent and Young Adult Oncology.

Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?
Muffly, L., & Curran, E. (2019). Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit? Hematology. American Society of Hematology. Education Program, 2019(1), 17–23.

Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults.
Wang, A. Y., Muffly, L. S., & Stock, W. (2020). Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults. JCO Oncology Practice, JOP1900197.

Advance Directive Utilization Is Associated with Less Aggressive End-of-Life Care in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Cappell, K., Sundaram, V., Park, A., Shiraz, P., Gupta, R., Jenkins, P., … Muffly, L. (2018). Advance Directive Utilization Is Associated with Less Aggressive End-of-Life Care in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24(5), 1035–40.

Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era
Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., … Cunanan, K. (2020). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

Transplant Physicians' Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool
Mishra, A., Preussler, J. M., Al-Mansour, Z., Bachanova, V., Bhatt, V. R., Bredeson, C., … Artz, A. S. (2020). Transplant Physicians' Attitudes on Candidacy for Allogeneic Hematopoietic Cell Transplantation (HCT) in Older Patients: The Need for a Standardized Geriatric Assessment (GA) Tool. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26(3), S45–S46.

Prospective Randomized Study of Advance Directives in Allogeneic Hematopoietic Cell Transplant Recipients
Muffly, L., Ramirez, Y., Burnash, S., Bisetti, E., Rezvani, A., & Sundaram, V. (2020). Prospective Randomized Study of Advance Directives in Allogeneic Hematopoietic Cell Transplant Recipients. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26(3), S199.

Feasibility of Centralized Electronic Patient-Reported Outcome (ePRO) Collection By an Outcome Registry, a CIBMTR Study of Patients on the Centers for Medicaid & Medicare Coverage with Evidence Development (CMS CED) Myelodysplasia Protocol
Shaw, B. E., Burns, L. J., Mattila, D., Mussetter, A., Chen, M., Vasu, S., … Flynn, K. (2020). Feasibility of Centralized Electronic Patient-Reported Outcome (ePRO) Collection By an Outcome Registry, a CIBMTR Study of Patients on the Centers for Medicaid & Medicare Coverage with Evidence Development (CMS CED) Myelodysplasia Protocol. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia.
Lee, C. J., Kim, S., Tecca, H. R., Bo-Subait, S., Phelan, R., Brazauskas, R., … Muffly, L. S. (2020). Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Advances, 4(6), 983–92.

The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia.
Shiraz, P., Payne, K. J., & Muffly, L. (2020). The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences, 21(6).

Access to specialized care and outcomes in adults with acute leukemias.
Muffly, L., & Bhatt, V. R. (2020). Access to specialized care and outcomes in adults with acute leukemias. Blood Advances, 4(7), 1538.

Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy.
Yurkiewicz, I., Craig, J., & Muffly, L. (2020). Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy. Current Hematologic Malignancy Reports.

Access to specialized care and outcomes in adults with acute leukemias
Muffly, L., & Bhatt, V. R. (2020). Access to specialized care and outcomes in adults with acute leukemias. BLOOD ADVANCES, 4(7), 1538.

Calcineurin-inhibitor induced pain syndrome after stem cell transplant.
Varma, A., Loya, J., Junaid Hussain, M., Don Yun, H., Gobbi, E. K., Reimer, A., … Muffly, L. (2020). Calcineurin-inhibitor induced pain syndrome after stem cell transplant. Leukemia & Lymphoma, 1–4.

Treatment Complications and Survival Among Children and Young Adults With Acute Lymphoblastic Leukemia.
Alvarez, E. M., Malogolowkin, M., Hoch, J. S., Li, Q., Brunson, A., Pollock, B. H., … Keegan, T. H. (2020). Treatment Complications and Survival Among Children and Young Adults With Acute Lymphoblastic Leukemia. JCO Oncology Practice, JOP1900572.

Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit?
Muffly, L., & Curran, E. (2019). Pediatric-inspired protocols in adult acute lymphoblastic leukemia: are the results bearing fruit? HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 17–23.

Late Effects in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia.
Muffly, L., Maguire, F. B., Li, Q., Kennedy, V., & Keegan, T. H. (2020). Late Effects in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia. JNCI Cancer Spectrum, 4(4), pkaa025.

Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.
Lemieux, C., Muffly, L. S., Rezvani, A., Lowsky, R., Iberri, D. J., Craig, J. K., … Sidana, S. (2020). Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation.

How I Approach the Patient Who Has MRD or Relapse After Transplant.
Muffly, L. (2020). How I Approach the Patient Who Has MRD or Relapse After Transplant. Clinical Lymphoma, Myeloma & Leukemia, 20 Suppl 1, S32–S33.

Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.
Weng, W.-K. K., Arai, S., Rezvani, A., Johnston, L., Lowsky, R., Miklos, D., … Kim, Y. H. (2020). Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Advances, 4(18), 4474–82.

How I Approach the Patient Who Has MRD or Relapse After Transplant
Muffly, L. (2020). How I Approach the Patient Who Has MRD or Relapse After Transplant. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 20, S32–S33.

Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.
Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., … Sidana, S. (2020). Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation.

Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin.
Ladha, A., Mannis, G., & Muffly, L. (2020). Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin. Leukemia & Lymphoma, 1–7.

Philadelphia chromosome positive acute lymphoblastic leukemia in adults: Therapeutic options and dilemmas in 2020.
Muffly, L., & Kebriaei, P. (2020). Philadelphia chromosome positive acute lymphoblastic leukemia in adults: Therapeutic options and dilemmas in 2020. Seminars in Hematology, 57(3), 137–41.

Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
Sica, R. A., Spinner, M. A., Tamaresis, J. S., Advani, R. H., Johnston, L. J., Lowsky, R., … Arai, S. (2019). Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. BLOOD. AMER SOC HEMATOLOGY.

Dose-Intense BCNU/Melphalan Regimen Followed By Autologous Hematopoietic Cell Transplantation (AHCT) Results in Prolonged PFS in Myeloma Patients
Gandhi, A., Rezvani, A., Lowsky, R., Johnston, L., Shizuru, J. A., Miklos, D. B., … Weng, W.-K. (2019). Dose-Intense BCNU/Melphalan Regimen Followed By Autologous Hematopoietic Cell Transplantation (AHCT) Results in Prolonged PFS in Myeloma Patients. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)
Schultz, L. M., Muffly, L. S., Spiegel, J. Y., Ramakrishna, S., Hossain, N., Baggott, C., … Davis, K. L. (2019). Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL). BLOOD. AMER SOC HEMATOLOGY.

Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel
Good, Z., Spiegel, J. Y., Sahaf, B., Malipatlolla, M. B., Frank, M. J., Baird, J., … Mackall, C. L. (2019). Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel. BLOOD. AMER SOC HEMATOLOGY.

Allogeneic hematopoietic cell transplantation (alloHCT) for patients over 65 years old is not associated with worse symptoms/function than younger patients - a Center for International Blood and Marrow Transplant Research (CIBMTR) study
Shaw, B., Brazauskas, R., Burns, L. J., Mattila, D., Musseter, A., Chen, M., … Flynn, K. E. (2020). Allogeneic hematopoietic cell transplantation (alloHCT) for patients over 65 years old is not associated with worse symptoms/function than younger patients - a Center for International Blood and Marrow Transplant Research (CIBMTR) study. QUALITY OF LIFE RESEARCH. SPRINGER.

Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML.
Ladha, A., Hui, G., Cheung, E., Berube, C., Coutre, S. E., Gotlib, J., … Mannis, G. N. (2021). Routine use of gemtuzumab ozogamicin in 7?+?3-based inductions for all 'non-adverse' risk AML. Leukemia & Lymphoma, 1–6.

CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.
Baird, J. H., Frank, M. J., Craig, J., Patel, S., Spiegel, J. Y., Sahaf, B., … Muffly, L. (2020). CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma. Blood.

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., … Sidana, S. (2021). Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. BLOOD ADVANCES, 5(1), 143–55.

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., … Sidana, S. (2021). Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Advances, 5(1), 143–155.

Assessment of Measurable Residual Disease (MRD) in Adult Patients With Acute Lymphocytic Leukemia: Best Use and a Case Report
Muffly, L. (2020). Assessment of Measurable Residual Disease (MRD) in Adult Patients With Acute Lymphocytic Leukemia: Best Use and a Case Report. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 18(3).

Clinical Actionability of Measurable Residual Disease (MRD) Assessment in the Management of Patients With Hematologic Malignancies: A Case-Based Monograph
Wolf, J., Fonseca, R., & Muffly, L. (2020). Clinical Actionability of Measurable Residual Disease (MRD) Assessment in the Management of Patients With Hematologic Malignancies: A Case-Based Monograph. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 18(3).

Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Rezvani, A., Lowsky, R., Frank, M. J., … Sidana, S. (2020). Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).
Tam, E. L., Iberri, D. J., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M. J., … Sidana, S. (2020). Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML.
El Chaer, F., Borate, U., Dulery, R., Holtan, S. G., Law, A. D., Muffly, L., … Hourigan, C. S. (2021). Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML. Blood Advances, 5(6), 1757–59.

Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
Liang, E. C., Muffly, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., … Sidana, S. (2021). Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy.

Prospective Randomized Study of Advance Directives in Allogeneic Hematopoietic Cell Transplant Recipients.
Tan, I. T., Sundaram, V., Ramirez, Y., Burnash, S., Kate Tierney, D., & Muffly, L. S. (2021). Prospective Randomized Study of Advance Directives in Allogeneic Hematopoietic Cell Transplant Recipients. Transplantation and Cellular Therapy.

Assessment of measurable residual disease (MRD) in adult patients with acute lymphocytic leukemia: best use and a case report.
Muffly, L. (2020). Assessment of measurable residual disease (MRD) in adult patients with acute lymphocytic leukemia: best use and a case report. Clinical Advances in Hematology & Oncology : H&O, 18 Suppl 9(3), 10–14.

Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph.
Wolf, J., Fonseca, R., & Muffly, L. (2020). Clinical actionability of measurable residual disease (MRD) assessment in the management of patients with hematologic malignancies: a case-based monograph. Clinical Advances in Hematology & Oncology : H&O, 18 Suppl 9(3), 1–16.

Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States.
Bhatt, N. S., Brazauskas, R., Salit, R. B., Syrjala, K., Bo-Subait, S., Tecca, H., … Shaw, B. (2021). Return to Work Among Young Adult Survivors of Allogeneic Hematopoietic Cell Transplantation in the United States. Transplantation and Cellular Therapy.

Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.
Johnsrud, A., Ladha, A., Muffly, L., Shiraz, P., Goldstein, G., Osgood, V., … Sidana, S. (2021). Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era. Transplantation and Cellular Therapy.

Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy
Hossain, N. M., Dahiya, S., Le, R., Abramian, A. M., Kong, K. A., Muffly, L. S., & Miklos, D. B. (2019). Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy. LEUKEMIA & LYMPHOMA, 60(2), 503–506.

Chronic medical conditions and late effects after acute myeloid leukaemia in adolescents and young adults: a population-based study.
Abrahao, R., Huynh, J. C., Benjamin, D. J., Li, Q. W., Winestone, L. E., Muffly, L., & Keegan, T. H. (2021). Chronic medical conditions and late effects after acute myeloid leukaemia in adolescents and young adults: a population-based study. International Journal of Epidemiology, 50(2), 663–674.

Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.
Lemieux, C., Muffly, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., … Sidana, S. (2021). Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation.

Late Effects and Subsequent Neoplasms in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Based Analysis Including Impact of Front-Line Regimen Type
Muffly, L. S., Maguire, F., Li, Q., Kennedy, V., & Keegan, T. H. M. (2019). Late Effects and Subsequent Neoplasms in Survivors of Adolescent and Young Adult Acute Lymphoblastic Leukemia: A Population-Based Analysis Including Impact of Front-Line Regimen Type. BLOOD. AMER SOC HEMATOLOGY.

Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California
Alvarez, E., Muffly, L., Li, Q., Brunson, A., Wun, T., Chamberlain, L., & Keegan, T. (2018). Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California. LEUKEMIA & LYMPHOMA, 59(10), 2482–2484.

Improved survival among children and adolescent and young adults with acute lymphoblastic leukemia (ALL) treated at specialized cancer centers in California.
Alvarez, E. M., Malogolowkin, M. H., Li, Q., Muffly, L. S., Wun, T., & Keegan, T. (2018). Improved survival among children and adolescent and young adults with acute lymphoblastic leukemia (ALL) treated at specialized cancer centers in California. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report
Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., … Arai, S. (2021). Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report. BONE MARROW TRANSPLANTATION. SPRINGERNATURE.

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Spiegel, J. Y., Patel, S., Muffly, L., Hossain, N. M., Oak, J., Baird, J. H., … Miklos, D. B. (2021). CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine.

Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.
Lazaryan, A., Dolan, M., Zhang, M.-J., Wang, H.-L., Kharfan-Dabaja, M. A., Marks, D. I., … Weisdorf, D. (2021). Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica, 106(8), 2295–2296.

Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
Muffly, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., … Miklos, D. B. (2021). Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Advances, 5(16), 3147–3151.

Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: A population-based analysis in the modern era.
Kennedy, V. E., Keegan, T. H., Li, Q., Maguire, F. B., & Muffly, L. S. (2021). Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: A population-based analysis in the modern era. Cancer.

Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy.
Johnsrud, A. J., Craig, J., Baird, J. H., Spiegel, J. Y., Muffly, L., Zehnder, J. L., … Sidana, S. (2021). Incidence and Risk Factors Associated with Bleeding and Thrombosis Following Chimeric Antigen Receptor T Cell Therapy. Blood Advances.

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Systematic Review and Meta-Analysis
Grover, P., Veilleux, O., Tian, L., Sun, R., Previtera, M., Curran, E., & Muffly, L. (2021). Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Systematic Review and Meta-Analysis. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.

Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD-Mutated AML Following Allogeneic Hematopoietic Cell Transplantation
Liang, E. C., Chen, C., Lu, R., Mannis, G. N., & Muffly, L. (2021). Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD-Mutated AML Following Allogeneic Hematopoietic Cell Transplantation. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.

Measurable Residual Disease in Acute Lymphoblastic Leukemia: Optimization and Innovation in 2021 and Beyond
Muffly, L. (2021). Measurable Residual Disease in Acute Lymphoblastic Leukemia: Optimization and Innovation in 2021 and Beyond. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.

Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.
Wieduwilt, M. J., Metheny, L., Zhang, M.-J., Wang, H.-L., Estrada-Merly, N., Marks, D. I., … Saber, W. (2021). Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances.

Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation.
Liang, E. C., Chen, C., Lu, R., Mannis, G. N., & Muffly, L. (2021). Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation.

Chimeric Antigen Receptor-T Cell Therapy in Adults with B-Cell Acute Lymphoblastic Leukemia: A Systematic Review.
Grover, P., Veilleux, O., Tian, L., Sun, R., Previtera, M., Curran, E., & Muffly, L. (2021). Chimeric Antigen Receptor-T Cell Therapy in Adults with B-Cell Acute Lymphoblastic Leukemia: A Systematic Review. Blood Advances.

Historical perspective and a glance into the antibody-based conditioning regimens: A new era in the horizon?
El Fakih, R., Lazarus, H. M., Muffly, L., Altareb, M., Aljurf, M., & Hashmi, S. K. (2021). Historical perspective and a glance into the antibody-based conditioning regimens: A new era in the horizon? Blood Reviews, 100892.

Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.
Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., … Miklos, D. B. (2021). Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., … Sidana, S. (2021). Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. BLOOD ADVANCES, 5(21), 4465–4475.

Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403.
Raychaudhuri, S., Yurkiewicz, I., Mannis, G. N., Medeiros, B. C., Coutre, S. E., Muffly, L. S., & Liedtke, M. (2021). Event free survival in adults with relapsed ALL who underwent front-line therapy with CALGB 10403. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Implementation of a clinic to facilitate the transition from pediatric to adult cancer survivorship care.
Smith, S. M., Jin, A., Simon, P., Clayton, A., Benedict, C., Liedtke, M., … Schapira, L. (2021). Implementation of a clinic to facilitate the transition from pediatric to adult cancer survivorship care. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.
Luznik, L., Pasquini, M. C., Logan, B., Soiffer, R. J., Wu, J., Devine, S. M., … Perales, M.-A. (2021). Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2102293.

Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry.
Cusatis, R., Flynn, K. E., Vasu, S., Pidala, J., Muffly, L., Uberti, J., … Shaw, B. (2021). Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry. Transplantation and Cellular Therapy.

Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.
Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., … Arai, S. (1800). Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report. Transplantation and Cellular Therapy.

Correction to: Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation.
Liang, E. C., Chen, C., Lu, R., Mannis, G. N., & Muffly, L. (2022). Correction to: Measurable residual disease status and FLT3 inhibitor therapy in patients with FLT3-ITD mutated AML following allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation.

Outcomes of Allogeneic Transplantation after Hypomethylating Agents with Venetoclax in Acute Myeloid Leukemia.
Kennedy, V. E., Hui, G., Azenkot, T., Gaut, D., Wieduwilt, M. J., Oliai, C., … Mannis, G. N. (2022). Outcomes of Allogeneic Transplantation after Hypomethylating Agents with Venetoclax in Acute Myeloid Leukemia. American Journal of Hematology.

Controversies in the Treatment of Adolescents and Young Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
Grover, P., & Muffly, L. (2022). Controversies in the Treatment of Adolescents and Young Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Current Oncology Reports.

Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum.
Curran, E., Muffly, L., & Luskin, M. R. (2022). Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 42, 1–11.

Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.
Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., … Muffly, L. (2022). Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy.

Measurable residual disease in acute lymphoblastic leukemia: techniques and therapeutic utility.
Muffly, L. (2022). Measurable residual disease in acute lymphoblastic leukemia: techniques and therapeutic utility. Clinical Advances in Hematology & Oncology : H&O, 20(7), 419–421.

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.
Muffly, L., Yin, J., Jacobson, S., Wall, A., Quiroz, E., Advani, A. S., … Stock, W. (2022). Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. Blood Advances, 6(14), 4085–4092.

Measurable Residual Disease in Acute Lymphoblastic Leukemia: Techniques and Therapeutic Utility
Muffly, L. (2022). Measurable Residual Disease in Acute Lymphoblastic Leukemia: Techniques and Therapeutic Utility. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 20(7), 419–421.

Treatment-related toxicities associated with hospitalization in children, adolescents, and young adults with acute lymphoblastic leukemia: population level analysis.
Namjoshi, N. S., Keegan, T. H., Li, Q. C., Chung, J. H., Rosenthal, J. L., Winestone, L. E., … Alvarez, E. M. (2022). Treatment-related toxicities associated with hospitalization in children, adolescents, and young adults with acute lymphoblastic leukemia: population level analysis. Leukemia & Lymphoma, 1–9.

Mgta-145+Plerixafor Provides GCSFFree Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study
Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S., Tamaresis, J., Le, A., … Miklos, D. B. (2021). Mgta-145+Plerixafor Provides GCSFFree Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study. BLOOD. AMER SOC HEMATOLOGY.

Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors
Arpita, G., Moroz, A., Muffly, L., Shiraz, P., Schachter, L., Fernhoff, N. B., … Meyer, E. H. (2021). Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors. BLOOD. AMER SOC HEMATOLOGY.

Do PROs Tell the Whole Story? Differential Outcomes Based on PatientReported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy
Tan, I., Cusatis, R., Crawford, E., Thiengmany, A., Piehowski, C., Akinola, I., … Sidana, S. (2021). Do PROs Tell the Whole Story? Differential Outcomes Based on PatientReported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy. BLOOD. AMER SOC HEMATOLOGY.

Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study
Cusatis, R., Tan, I., Piehowski, C., Akinola, I., Crawford, E., Craig, J., … Sidana, S. (2021). Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study. BLOOD. AMER SOC HEMATOLOGY.

First Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia: Associated Health Care Resource Use and Costs
Muffly, L., Young, C., Nimke, D., Sullivan, L., Feng, Q., & Pandya, B. J. (2021). First Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia: Associated Health Care Resource Use and Costs. BLOOD. AMER SOC HEMATOLOGY.

Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a US Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with US Population-Level Data
Muffly, L., Yin, J., Jacobson, S., Advani, A., Luger, S. M., Tallman, M. S., … Stock, W. (2021). Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a US Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with US Population-Level Data. BLOOD. AMER SOC HEMATOLOGY.

Post-infusion CAR T-Reg cells identify patients resistant to CD19-CAR therapy
Good, Z., Spiegel, J. Y., Sahaf, B., Malipatlolla, M. B., Ehlinger, Z. J., Kurra, S., … Mackall, C. L. (2022). Post-infusion CAR T-Reg cells identify patients resistant to CD19-CAR therapy. NATURE MEDICINE.

SOHO State of the Art Updates and Next Questions: Measurable Residual Disease in Acute Lymphoblastic Leukemia - Optimization and Innovation in 2022 and Beyond.
Dekker, S. E., Leonard, J., & Muffly, L. (2022). SOHO State of the Art Updates and Next Questions: Measurable Residual Disease in Acute Lymphoblastic Leukemia - Optimization and Innovation in 2022 and Beyond. Clinical Lymphoma, Myeloma & Leukemia.

CT-095 Disparities and Incomplete Capture of Race/Ethnicity Data in Adults With Hematologic Malignancies Referred for Cellular Therapies.
Molina, A., & Muffly, L. (2022). CT-095 Disparities and Incomplete Capture of Race/Ethnicity Data in Adults With Hematologic Malignancies Referred for Cellular Therapies. Clinical Lymphoma, Myeloma & Leukemia, 22 Suppl 2, S433–S434.

Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD Mutated AML Following Allogeneic Hematopoietic Cell Transplantation
Liang, E. C., Chen, C., Lu, R., Mannis, G. N., & Muffly, L. (2021). Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD Mutated AML Following Allogeneic Hematopoietic Cell Transplantation. BLOOD. AMER SOC HEMATOLOGY.

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia
Muffly, L., Yin, J., Jacobson, S., Wall, A., Quiroz, E., Advani, A. S., … Stock, W. (2022). Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. BLOOD ADVANCES, 6(14), 4085–4092.

Linking the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry to the California Cancer Registry and California Hospital Patient Discharge Data.
Keegan, T. H., Brunson, A., Cooley, J. J., Schonfeld, S. J., Meyer, C. L., Valcarcel, B., … Morton, L. M. (2022). Linking the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry to the California Cancer Registry and California Hospital Patient Discharge Data. Transplantation and Cellular Therapy.

Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy
Satyanarayan, S., Spiegel, J., Hovsepian, D., Markert, M., Thomas, R., Muffly, L., … Scott, B. J. (2022). Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy. NEUROHOSPITALIST.

Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.
Saygin, C., Cannova, J., Stock, W., & Muffly, L. (2022). Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients. Haematologica, 107(12), 2783–2793.

End-of-Life Care Intensity in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Population-Level Analysis
Johnston, E. E., Muffly, L., Alvarez, E., Saynina, O., Sanders, L. M., Bhatia, S., & Chamberlain, L. J. (2018). End-of-Life Care Intensity in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: A Population-Level Analysis. JOURNAL OF CLINICAL ONCOLOGY, 36(30).

Impact of Higher-Dose Total Body Irradiation Conditioning on Outcome of an Allogeneic Hematopoietic Cell Transplant (HCT) in the Modern Era
Sabloff, M., Wang, T., Zhu, X., Artz, A. S., Adekola, K., Abraham, A., … Mineishi, S. (2017). Impact of Higher-Dose Total Body Irradiation Conditioning on Outcome of an Allogeneic Hematopoietic Cell Transplant (HCT) in the Modern Era. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC.

Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions
Kennedy, V. E., & Muffly, L. S. (2019). Assessment of older adult candidates for allogeneic hematopoietic cell transplantation: updates and remaining questions. EXPERT REVIEW OF HEMATOLOGY, 12(2), 99–106.

Symptom burdens and coping strategies in adolescent and young adult (AYA) cancer survivors with hematologic malignancies.
Hlubocky, F. J., Muffly, L. S., Gomez, J. X., Breitenbach, K., McNeer, J. L., Stock, W., & Daugherty, C. (2016). Symptom burdens and coping strategies in adolescent and young adult (AYA) cancer survivors with hematologic malignancies. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Another reason to encourage psychosocial risk assessment in hematopoietic cell transplantation
Muffly, L., & Artz, A. (2018). Another reason to encourage psychosocial risk assessment in hematopoietic cell transplantation. BONE MARROW TRANSPLANTATION, 53(11), 1416–1417.

Financial toxicity in children, adolescent, and young adult cancer patients and their families: A large national registry analysis from the family reach foundation
Muffly, L. S., Tardif, C., & de Souza, J. (2016). Financial toxicity in children, adolescent, and young adult cancer patients and their families: A large national registry analysis from the family reach foundation. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Death anxiety, psychological distress, and quality of life (QOL) in adolescent and young adult (AYA) cancer patients with hematologic malignancies in early survivorship.
Hlubocky, F. J., Muffly, L. S., Gomez, J. X., Breitenbach, K., Cella, D., McNeer, J. L., … Daugherty, C. (2016). Death anxiety, psychological distress, and quality of life (QOL) in adolescent and young adult (AYA) cancer patients with hematologic malignancies in early survivorship. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Substance use, psychological distress, and quality of life (QOL) in adolescent and young adult (AYA) cancer patients with hematologic malignancies in early survivorship.
Hlubocky, F. J., Muffly, L. S., Gomez, J., Breitenbach, K., Lappe, M., Stock, W., & Daugherty, C. (2016). Substance use, psychological distress, and quality of life (QOL) in adolescent and young adult (AYA) cancer patients with hematologic malignancies in early survivorship. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.

Hematopoietic cell transplantation in T-cell non-Hodgkin's lymphomas
Muffly, L. S., & Smith, S. M. (2014). Hematopoietic cell transplantation in T-cell non-Hodgkin's lymphomas. CANCER CONSULT: EXPERTISE FOR CLINICAL PRACTICE, 339–344.

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy
Abramson, J. S., Feldman, T., Kroll-Desrosiers, A. R., Muffly, L. S., Winer, E., Flowers, C. R., … Evens, A. M. (2014). Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. ANNALS OF ONCOLOGY, 25(11), 2211–2217.

Prognosis in diffuse large B-cell lymphoma The Picture Continues to Come Into Focus
Muffly, L. S., & Smith, S. M. (2013). Prognosis in diffuse large B-cell lymphoma The Picture Continues to Come Into Focus. CANCER, 119(6), 1129–1131.

Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy.
Satyanarayan, S., Spiegel, J., Hovsepian, D., Markert, M., Thomas, R., Muffly, L., … Scott, B. J. (2023). Continuous EEG monitoring detects nonconvulsive seizure and Ictal-Interictal Continuum abnormalities in moderate to severe ICANS following systemic CAR-T therapy. The Neurohospitalist, 13(1), 53–60.

Sequencing Antigen-Targeting Antibodies and Cellular Therapies in Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Aldoss, I., Shah, B. D., Park, J. H., Muffly, L., Logan, A. C., Brown, P., … Jabbour, E. J. (2023). Sequencing Antigen-Targeting Antibodies and Cellular Therapies in Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. American Journal of Hematology.

Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents.
Spinner, M. A., Sica, R. A., Tamaresis, J. S., Lu, Y., Chang, C., Lowsky, R., … Arai, S. (2023). Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. Blood.

Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
Philip, S., Lowsky, R., Johnston, L. J., Arai, S., Meyer, E. H., Negrin, R. S., … Agrawal, V. (2022). Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era. BLOOD. AMER SOC HEMATOLOGY.

Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease
Chin, M., Shizuru, J. A., Muffly, L., Shiraz, P., Johnston, L. J., Lowsky, R., … Arai, S. (2022). Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease. BLOOD. AMER SOC HEMATOLOGY.

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
Oliai, C., Hoeg, R. T., Pavlova, A., Gandhi, A., Muffly, L., Mehta, R. S., … Meyer, E. H. (2022). Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity. BLOOD. AMER SOC HEMATOLOGY.

CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study
Jeyakumar, N., Ramakrishna, S., Frank, M. J., Sahaf, B., Feldman, S. A., Miklos, D. B., … Schultz, L. M. (2022). CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study. BLOOD. AMER SOC HEMATOLOGY.

Impact on caregivers and families of patients receiving chimeric antigen receptor T-cell therapy: a prospective longitudinal mixed methods study
Litovich, C., Piehowski, C., Akinola, I., Crawford, E., D'Souza, A., Frank, M., … Cusatis, R. (2022). Impact on caregivers and families of patients receiving chimeric antigen receptor T-cell therapy: a prospective longitudinal mixed methods study. QUALITY OF LIFE RESEARCH. SPRINGER.

Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation
Liang, E. C., Dekker, S. E., Sabile, J. M. G., Torelli, S., Zhang, A., Miller, K., … Muffly, L. (2022). Ultra-Sensitive Next-Generation Sequencing Establishes the Prognostic Value of Very Low MRD in Adults with Acute Lymphoblastic Leukemia Undergoing Hematopoietic Cell Transplantation. BLOOD. AMER SOC HEMATOLOGY.

Geographical Barriers to Accessing Specialty Cancer Care Among Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Muffly, L., Garcia, A., Miller, K., Keegan, T. H. M., & Parsons, H. (2022). Geographical Barriers to Accessing Specialty Cancer Care Among Adolescents and Young Adults with Acute Lymphoblastic Leukemia. BLOOD. AMER SOC HEMATOLOGY.

Interim Update on the 'Watch' Registry, a Real-World Observational Study Using Clonoseq (R) to Monitor MRD in Lymphoid Malignancies
Patel, K., Svoboda, J., Shah, B. D., Cheson, B. D., Azzi, G., Patel, K., … Leonard, J. (2022). Interim Update on the 'Watch' Registry, a Real-World Observational Study Using Clonoseq (R) to Monitor MRD in Lymphoid Malignancies. BLOOD. AMER SOC HEMATOLOGY.

Disparities and Incomplete Capture of Race/Ethnicity Data in Adults With Hematologic Malignancies Referred for Cellular Therapies
Molina, A., & Muffly, L. (2022). Disparities and Incomplete Capture of Race/Ethnicity Data in Adults With Hematologic Malignancies Referred for Cellular Therapies. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.

Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma
Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamaresis, J., Patil, S., Hanson, P. J., … Dahiya, S. (2022). Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma. BLOOD. AMER SOC HEMATOLOGY.

The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes
Philip, S., Srinagesh, H. K., Hamilton, M. P., Gentille, C., Mina, A., Arai, S., … Frank, M. J. (2022). The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes. BLOOD. AMER SOC HEMATOLOGY.

Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M. S., Good, Z., … Alizadeh, A. A. (2022). Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects. BLOOD. AMER SOC HEMATOLOGY.

Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation
Schultz, L. M., Ramakrishna, S., Baskar, R., Richards, R. M., Moon, J., Baggott, C., … Davis, K. L. (2022). Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation. BLOOD. AMER SOC HEMATOLOGY.

Real World Outcomes in Acute Myeloid Leukemia Patients Following Post Hematopoietic Stem-Cell Transplantation Maintenance Treatment with Midostaurin or Sorafenib: A US Retrospective Cohort Study
Muffly, L., Young, C., Xie, B., Block, A., Touya, M., & Pandya, B. J. (2022). Real World Outcomes in Acute Myeloid Leukemia Patients Following Post Hematopoietic Stem-Cell Transplantation Maintenance Treatment with Midostaurin or Sorafenib: A US Retrospective Cohort Study. BLOOD. AMER SOC HEMATOLOGY.

Utilization of Autologous HCT in Multiple Myeloma: A Novel Linkage of CIBMTR, Cancer Registry and Hospitalization Data in California
Esteghamat, N. S., Brunson, A. M., Wun, T., Rosenberg, A. S., Cooley, J. J. P., Schonfeld, S. J., … Keegan, T. H. M. (2022). Utilization of Autologous HCT in Multiple Myeloma: A Novel Linkage of CIBMTR, Cancer Registry and Hospitalization Data in California. BLOOD. AMER SOC HEMATOLOGY.

Subsequent Solid Neoplasms Following Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies: Comparing Center for International Blood and Marrow Transplant Research (CIBMTR) and California Cancer Registry (CCR) Data
Schonfeld, S. J., Valcarcel, B., Meyer, C. L., Brunson, A. M., Cooley, J. J. P., Abrahao, R., … Morton, L. M. (2022). Subsequent Solid Neoplasms Following Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies: Comparing Center for International Blood and Marrow Transplant Research (CIBMTR) and California Cancer Registry (CCR) Data. BLOOD. AMER SOC HEMATOLOGY.

Comparison of Vital Status and Cause-Specific Mortality after Hematopoietic Cell Transplantation between the Center for International Blood and Marrow Transplant Research and the California Cancer Registry: A Record-Linkage Analysis from 1991 to 2018
Valcarcel, B., Schonfeld, S. J., Meyer, C. L., Brunson, A. M., Cooley, J. J. P., Abrahao, R., … Morton, L. M. (2022). Comparison of Vital Status and Cause-Specific Mortality after Hematopoietic Cell Transplantation between the Center for International Blood and Marrow Transplant Research and the California Cancer Registry: A Record-Linkage Analysis from 1991 to 2018. BLOOD. AMER SOC HEMATOLOGY.

Reverse fate mapping of CD19-targeted CAR T cells in patients with large B-cell lymphoma
Good, Z., Hamilton, M. P., Spiegel, J. Y., Kurra, S., Desai, M., Prabhu, S., … Mackall, C. L. (2022). Reverse fate mapping of CD19-targeted CAR T cells in patients with large B-cell lymphoma. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.

Next-Generation Sequencing-Based MRD in Adults with ALL Undergoing Hematopoietic Cell Transplantation.
Liang, E. C., Dekker, S. E., Sabile, J. M., Torelli, S., Zhang, A., Miller, K., … Muffly, L. (2023). Next-Generation Sequencing-Based MRD in Adults with ALL Undergoing Hematopoietic Cell Transplantation. Blood Advances.

Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States.
Muffly, L., Young, C., Feng, Q., Nimke, D., & Pandya, B. J. (2023). Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States. Leukemia & Lymphoma, 1–8.

Implementation of a Pilot Clinic for Pediatric to Adult Cancer Survivorship Transitions.
Jin, A. H., Simon, P. J., Clayton, A., Benedict, C., Liedtke, M., Muffly, L., … Smith, S. M. (2023). Implementation of a Pilot Clinic for Pediatric to Adult Cancer Survivorship Transitions. Journal of Adolescent and Young Adult Oncology.

Specialty cancer care and survival in AYA ALL: A US multi-state analysis.
Muffly, L. S., Miller, K., Maguire, F. B., Li, Q., Parsons, H. M., & Keegan, T. (2023). Specialty cancer care and survival in AYA ALL: A US multi-state analysis. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.
Roloff, G., Faramand, R., Aldoss, I., Kopmar, N. E., Schwartz, M., Dekker, S. E., … Muffly, L. S. (2023). Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.

INSPIRED Symposium Part 4A: Access to CAR T cell Therapy in Unique Populations with B-cell Acute Lymphoblastic Leukemia.
Winestone, L. E., Bhojwani, D., Ghorashian, S., Muffly, L., Leahy, A. B., Chao, K., … Rheingold, S. R. (2023). INSPIRED Symposium Part 4A: Access to CAR T cell Therapy in Unique Populations with B-cell Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy.

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.
Sidana, S., Hosoya, H., Jensen, A., Liu, L., Goyal, A., Hovanky, V., … Janakiram, M. (2023). Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. Blood Cancer Journal, 13(1), 158.

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease (GvHD) and Toxicity
Salhotra, A., Oliai, C., Hoeg, R. T., Gandhi, A., Muffly, L., Srour, S. A., … Meyer, E. (2023). Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease (GvHD) and Toxicity. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.

Clinical Outcomes and Treatment Patterns in Adult Patients With FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication Positive Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the US and Canada: CIBMTR® (Center for International Blood and Marrow Transplant Research Analysis)
Burns, L. J., Pandya, B. J., Chen, K., Wang, T., Xie, B., Touya, M., … Muffly, L. (2023). Clinical Outcomes and Treatment Patterns in Adult Patients With FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication Positive Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the US and Canada: CIBMTR® (Center for International Blood and Marrow Transplant Research Analysis). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.

Impact of Specialized Treatment Setting on Survival in Adolescent and Young Adult ALL.
Muffly, L. S., Parsons, H. M., Miller, K., Li, Q., Brunson, A., & Keegan, T. H. (2023). Impact of Specialized Treatment Setting on Survival in Adolescent and Young Adult ALL. JCO Oncology Practice, OP2300373.

Comparison of vital status, cause of death, and follow-up after HCT in linked CIBMTR and California Cancer Registry data, 1991-2018.
Valcarcel, B., Schonfeld, S. J., Meyer, C. L., Brunson, A., Cooley, J. J., Abrahão, R., … Morton, L. M. (2023). Comparison of vital status, cause of death, and follow-up after HCT in linked CIBMTR and California Cancer Registry data, 1991-2018. Transplantation and Cellular Therapy.

Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD.
Bader, C. S., Pavlova, A., Lowsky, R., Muffly, L., Shiraz, P., Arai, S., … Meyer, E. (2023). Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD. Blood Advances.

PRECISION-ENGINEERED CELL THERAPY ORCA-T DEMONSTRATES HIGH RELAPSE-FREE SURVIVAL AT 1 YEAR WHILE REDUCING GRAFT-VERSUS-HOST DISEASE AND TOXICITY
Oliai, C., Hoeg, R., Pavlova, A., Gandhi, A., Muffly, L., Mehta, R., … Meyer, E. (2023). PRECISION-ENGINEERED CELL THERAPY ORCA-T DEMONSTRATES HIGH RELAPSE-FREE SURVIVAL AT 1 YEAR WHILE REDUCING GRAFT-VERSUS-HOST DISEASE AND TOXICITY. BONE MARROW TRANSPLANTATION. SPRINGERNATURE.

GVHD ASSESSMENT IN PHASE 1 STUDY OF BRIQUILIMAB (JSP191), LOW DOSE IRRADIATION AND FLUDARABINE CONDITIONING IN OLDER ADULTS WITH MDS/AML UNDERGOING ALLOGENEIC HCT
Youn, M., Muffly, L., Artz, A., Lee, C., Gandhi, A., Varma, A., … Pang, W. (2023). GVHD ASSESSMENT IN PHASE 1 STUDY OF BRIQUILIMAB (JSP191), LOW DOSE IRRADIATION AND FLUDARABINE CONDITIONING IN OLDER ADULTS WITH MDS/AML UNDERGOING ALLOGENEIC HCT. BONE MARROW TRANSPLANTATION. SPRINGERNATURE.

SOCIAL FUNCTIONING AFTER TRANSPLANTATION AND CELLULAR THERAPY: INITIAL PATIENT-REPORTED OUTCOMES RESULTS FROM THE CIBMTR
Cusatis, R., Ndifon, E., Mattila, D., Berman, L., Akinola, I., Kapfhammer, M., … Flynn, K. (2023). SOCIAL FUNCTIONING AFTER TRANSPLANTATION AND CELLULAR THERAPY: INITIAL PATIENT-REPORTED OUTCOMES RESULTS FROM THE CIBMTR. BONE MARROW TRANSPLANTATION. SPRINGERNATURE.

Utilization of Autologous Hematopoietic Cell Transplantation Over Time in Multiple Myeloma: A Population-Based Study.
Esteghamat, N. S., Brunson, A., Rosenberg, A. S., Schonfeld, S. J., Valcarcel, B., Abrahao, R., … Keegan, T. H. (2023). Utilization of Autologous Hematopoietic Cell Transplantation Over Time in Multiple Myeloma: A Population-Based Study. Clinical Lymphoma, Myeloma & Leukemia.

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias
Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., … Alizadeh, A. A. (2023). CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias. BLOOD. AMER SOC HEMATOLOGY.

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies
Oliai, C. H., Pantin, J. M., Hoeg, R. T., Muffly, L. S., Patel, S. S., Gandhi, A., … Meyer, E. H. (2023). Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies. BLOOD. AMER SOC HEMATOLOGY.

Final Results from Phase 1 Study of Briquilimab, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myeloid Leukemia in Complete Remission and Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation
Gandhi, A., Artz, A., Lee, C. J., Varma, A., Scott, B. L., Kwon, H.-S., … Muffly, L. S. (2023). Final Results from Phase 1 Study of Briquilimab, an Anti-CD117 Monoclonal Antibody, in Combination with Low Dose Irradiation and Fludarabine Conditioning, Shows Durable Remissions in Older Adults with Acute Myeloid Leukemia in Complete Remission and Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation. BLOOD. AMER SOC HEMATOLOGY.

Transcriptional Profiling Associated with CD22 CAR T Cell Clinical Response in LBCL
Kramer, A. M., Hamilton, M. P., Prabhu, S., Desai, M., Kuo, A., Ehlinger, Z., … Frank, M. J. (2023). Transcriptional Profiling Associated with CD22 CAR T Cell Clinical Response in LBCL. BLOOD. AMER SOC HEMATOLOGY.

Manufacturing of a Subsequent Autologous CAR-T Product after Prior CAR-T Is Safe and Feasible
Su, Y.-J., Kramer, A. M., Hamilton, M. P., Agarwal, N., Feldman, S., Sahaf, B., … Frank, M. J. (2023). Manufacturing of a Subsequent Autologous CAR-T Product after Prior CAR-T Is Safe and Feasible. BLOOD. AMER SOC HEMATOLOGY.

Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3ITD Variant Allele Frequency and Survival Are Highly Correlated
Levis, M. J., Hamadani, M., Logan, B. R., Jones, R. J., Singh, A. K., Litzow, M. R., … Chen, Y.-B. (2023). Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3ITD Variant Allele Frequency and Survival Are Highly Correlated. BLOOD. AMER SOC HEMATOLOGY.

Brexucabtagene Autoleucel in Adults with Relapsed/ Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)
Roloff, G. W., Aldoss, I., Kopmar, N. E., Lin, C., Dekker, S. E., Gupta, V. K., … Muffly, L. S. (2023). Brexucabtagene Autoleucel in Adults with Relapsed/ Refractory B-Cell ALL: Outcomes and Novel Insights from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA). BLOOD. AMER SOC HEMATOLOGY.

Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA)
Gupta, V. K., Roloff, G. W., Muffly, L. S., Aldoss, I., Kopmar, N. E., Lin, C., … Oliai, C. H. (2023). Impact of Prior Response to Blinatumomab on Outcomes of Brexucabtagene Autoleucel (Brexu-cel) in Adult Patients with Relapsed or Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA). BLOOD. AMER SOC HEMATOLOGY.

Age-Related Differences in Utilization of Allogeneic HCT for Acute Myeloid Leukemia in California: Results of a Population-Based, Novel Linked Dataset
Meyer, C. L., Keegan, T. H. M., Brunson, A., Auletta, J. J., Morton, L. M., Wun, T., … Muffly, L. S. (2023). Age-Related Differences in Utilization of Allogeneic HCT for Acute Myeloid Leukemia in California: Results of a Population-Based, Novel Linked Dataset. BLOOD. AMER SOC HEMATOLOGY.

Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study
Kopmar, N. E., Gooley, T., Roloff, G. W., Aldoss, I., Lin, C., Dekker, S. E., … Cassaday, R. D. (2023). Toxicity Profile of Brexucabtagene Autoleucel (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Patients (pts) with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from a Multicenter Real-World Outcomes Study. BLOOD. AMER SOC HEMATOLOGY.

The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
O'Connor, T. E., Lin, C., Roloff, G. W., Zhang, A., Aldoss, I., Faramand, R., … Dholaria, B. (2023). The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. BLOOD. AMER SOC HEMATOLOGY.

Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus
Villar-Prados, A., Meyer, E. H., Sutherland, K., Negrin, R. S., Arai, S., Frank, M. J., … McClellan, S. (2023). Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus. BLOOD. AMER SOC HEMATOLOGY.

CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-. Cytokine Signature
Srinagesh, H., Baird, J. H., Agarwal, N., Su, Y.-J., Kramer, A. M., Reschke, A., … Frank, M. J. (2023). CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-. Cytokine Signature. BLOOD. AMER SOC HEMATOLOGY.

Retrospective Analysis of Adolescent Young Adult Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated with the CALGB 10403 Regimen Since Completion of Trial Enrollment
DaSilva, B., Vyas, R. D., Darwin, A., Russel, K., Gilbert, J., Tan, V., … Muffly, L. S. (2023). Retrospective Analysis of Adolescent Young Adult Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated with the CALGB 10403 Regimen Since Completion of Trial Enrollment. BLOOD. AMER SOC HEMATOLOGY.

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation
Shah, N. N., Azzi, J., Cooper, B. W., Deol, A., DiPersio, J., Koura, D., … Koehne, G. (2023). Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. BLOOD. AMER SOC HEMATOLOGY.

Discordance between Next Generation Sequencing and BCR-ABL PCR Measurable Residual Disease in Adult Patients with Ph plus Acute Lymphoblastic Leukemia
Dekker, S. E., Sabile, J., Dasilva, B., Saygin, C., Schwartz, M., Raman, H. S., … Leonard, J. T. (2023). Discordance between Next Generation Sequencing and BCR-ABL PCR Measurable Residual Disease in Adult Patients with Ph plus Acute Lymphoblastic Leukemia. BLOOD. AMER SOC HEMATOLOGY.

The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Aldoss, I., Roloff, G. W., Advani, A. S., Kopmar, N. E., Lin, C., Dekker, S. E., … Muffly, L. S. (2023). The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL). BLOOD. AMER SOC HEMATOLOGY.

Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the RealWorld Outcomes Collaborative of CAR T in Adult ALL (ROCCA)
Lin, C., Tsai, S. B., Roloff, G. W., Zhang, A., Aldoss, I., Kopmar, N. E., … Faramand, R. (2023). Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the RealWorld Outcomes Collaborative of CAR T in Adult ALL (ROCCA). BLOOD. AMER SOC HEMATOLOGY.

Update for the 'Watch' Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies
Cowan, A. J., Patel, K., Svoboda, J., Shah, B. D., Cheson, B. D., Azzi, G., … Leonard, J. T. (2023). Update for the 'Watch' Registry, a Real-World Observational Study Using Clonoseq® to Monitor MRD in Lymphoid Malignancies. BLOOD. AMER SOC HEMATOLOGY.

Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3.
Levis, M. J., Hamadani, M., Logan, B., Jones, R. J., Singh, A. K., Litzow, M., … Chen, Y.-B. B. (2024). Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2302474.

CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.
Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., … Muffly, L. (2024). CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results. Leukemia.

CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.
Hamilton, M. P., Craig, E., Gentille Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., … Miklos, D. B. (2024). CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity. Blood Advances.

Management of post-autologous transplant relapse in patients with T-cell lymphomas.
Veilleux, O., Socola, F., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., … Weng, W.-K. K. (2024). Management of post-autologous transplant relapse in patients with T-cell lymphomas. American Journal of Hematology.

How I Use Next Generation Sequencing-MRD to Plan Approach and Prevent Relapse after HCT for Children and Adults with ALL.
Muffly, L., Liang, E. C., Dolan, J. G., & Pulsipher, M. A. (2024). How I Use Next Generation Sequencing-MRD to Plan Approach and Prevent Relapse after HCT for Children and Adults with ALL. Blood.

Travel-Time barriers to specialized cancer care for adolescents and young adults with acute leukemia.
Parsons, H. M., Muffly, L. S., Garcia, A., Zhang, A., Miller, K., Van Riper, D., … Keegan, T. H. (2024). Travel-Time barriers to specialized cancer care for adolescents and young adults with acute leukemia. JNCI Cancer Spectrum.

Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry.
Schonfeld, S. J., Valcarcel, B., Meyer, C. L., Shaw, B. E., Phelan, R., Rizzo, D., … Morton, L. M. (2024). Cumulative incidence estimates for solid tumors after HCT in the CIBMTR and California Cancer Registry. Blood Advances.

Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.
Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., … Dahiya, S. (2024). Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma. Journal for Immunotherapy of Cancer, 12(7).

A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.
Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., … Muffly, L. (2024). A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia. Blood.